Magnetic fluid hyperthermia induced by radiofrequency capacitive field for the treatment of transplanted subcutaneous tumors in rats
- Authors:
- Xu-Hong Li
- Peng-Fei Rong
- He-Kun Jin
- Wei Wang
- Jin-Tian Tang
View Affiliations
Affiliations: Department of Rehabilitation, the Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China, Department of Radiology, the Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China, Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Institute of Engineering and Physics, Tsinghua University, Beijing 100084, P.R. China
- Published online on: November 30, 2011 https://doi.org/10.3892/etm.2011.397
-
Pages:
279-284
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Magnetic fluid hyperthermia (MFH) induced by a magnetic field has become a new heating technology for the treatment of malignant tumors due to its ability to heat the tumor tissue precisely and properly, and due to its significant therapeutic effects. In this study, MFH induced by radiofrequency capacitive field (RCF) for the treatment of transplanted subcutaneous tumors in rats, was investigated. A total of 50 rats bearing subcutaneous tumors were randomly divided into five groups, including i) a pseudo‑treatment (PT) control group, ii) magnetic fluid (MF) group, iii) pure hyperthermia (PH) group, iv) magnetic fluid hyperthermia 1 (MFH1) group, and v) magnetic fluid hyperthermia 2 (MFH2) group. Tumors were irradiated for 30 min in the MFH1 group 24 h following injection of MF. Tumors were irradiated for 30 min in the MFH2 group 24 h following injection of MF, and irradiation was repeated for 30 min 72 h following injection of MF. Tumor volumes, tumor volume inhibition ratios and survival times in the rat model were examined. Temperatures of tumor cores and rims both rapidly reached the desired temperature (~50˚C) for tumor treatment within 5 to 10 min in the MFH1 and MFH2 groups, and we maintained this temperature level by manually adjusting the output power (70-130 W). Tumor volumes of the MFH1 and MFH2 groups were reduced compared to those of the PT, MF and PH groups. The inhibitory effect on tumor growth in the MFH2 group (91.57%) was higher compared to that in the MFH1 group (85.21%) and the other groups. The survival time of the MFH2 group (51.62±2.28 days) and MFH1 group (43.10±1.57 days) was increased compared to that of the PH, MF and PT groups. The results obtained show that MFH induced by RCF may serve as a potential and promising method for the treatment of tumors.
View Figures |
Figure 1
|
 |
Figure 2
|
 |
Figure 3
|
 |
Figure 4
|
 |
Figure 5
|
 |
Figure 6
|
View References
|
1.
|
RW HabashR BansalD KrewskiHT
AlhafidThermal therapy, part 1: an introduction to thermal
therapyCrit Rev Biomed
Engl34459489200610.1615/CritRevBiomedEng.v34.i6.2017725479
|
|
2.
|
PR StaufferEvolving technology for thermal
therapy of cancerInt J
Hyperthermia21731744200510.1080/0265673050033186816338856
|
|
3.
|
B HildebrandtB RauJ GellermannStandards
and perspectives in locoregional hyperthermiaWien Med
Wochenschr154148158200410.1007/s10354-004-0050-715182041
|
|
4.
|
ED HagerH DziamborD HöhmannD GallenbeckM
StephanC PopaDeep hyperthermia with radiofrequencies in patients
with liver metastases from colorectal cancerAnticancer
Res1934033408199910629627
|
|
5.
|
A JordanR ScholzP WustEffects of magnetic
fluid hyperthermia (MFH) on C3H mammary carcinoma in vivoInt J
Hyperthermia13587605199710.3109/026567397090235599421741
|
|
6.
|
M LatorreC RinaldiApplications of magnetic
nanoparticles in medicine: magnetic fluid hyperthermiaP R Health
Sci J28227238200919715115
|
|
7.
|
P CherukuriES GlazerSA CurleyTargeted
hyperthermia using metal nanoparticlesAdv Drug Deliv
Rev62339345201010.1016/j.addr.2009.11.00619909777
|
|
8.
|
MM ShenoiNB ShahRJ GriffinGM VercellottiJC
BischofNanoparticle preconditioning for enhanced thermal therapies
in cancerNanomedicine6545563201110.2217/nnm.10.15321542691
|
|
9.
|
X LuoL HuC SunL XiongY MiAn experimental
study of energy controllable steep pulse in the treatment of rat
with subcutaneous transplantive tumorSheng Wu Yi Xue Gong Cheng Xue
Za Zhi24492495200717713246
|
|
10.
|
FY ChengCH SuYS YangCharacterization of
aqueous dispersions of Fe(3)O(4) nanoparticles and their biomedical
applicationsBiomaterials26729738200510.1016/j.biomaterials.2004.03.01615350777
|
|
11.
|
A JordanR ScholzU GneveckowDescription and
characterization of the novel hyperthermia and
thermoablation-system MFH 300F for clinical magnetic fluid
hyperthermiaMed Phys1014441451200415259647
|
|
12.
|
CA CamargoME da SilvaRA da SilvaGZ JustoMC
Gomes-MarcondesH AoyamaInhibition of tumor growth by quercetin with
increase of survival and prevention of cachexia in Walker 256
tumor-bearing ratsBiochem Biophys Res
Commun406638642201110.1016/j.bbrc.2011.02.11121362404
|
|
13.
|
VL FlandersDA GervaisAblation of liver
metastases: current statusJ Vasc Interv
Radiol21S214222201010.1016/j.jvir.2010.01.04620656231
|
|
14.
|
ES GlazerSA CurleyRadiofrequency
field-induced thermal cytotoxicity in cancer cells treated with
fluorescent
nanoparticlesCancer11632853293201010.1002/cncr.2513520564640
|
|
15.
|
J CardinalJR KluneE ChoryG JeyabalanJS
KanziusM NalesnikDA GellerNoninvasive radiofrequency ablation of
cancer targeted by gold
nanoparticlesSurgery144125132200810.1016/j.surg.2008.03.03618656617
|
|
16.
|
R BanerjeeY KatsenovichL LagosM McIintoshX
ZhangCZ LiNanomedicine: magnetic nanoparticles and their biomedical
applicationsCurr Med
Chem1731203141201010.2174/09298671079195976520629620
|
|
17.
|
M JohannsenU GneveckowK TaymoorianThermal
therapy of prostate cancer using magnetic nanoparticlesActas Urol
Esp31660667200717896563
|
